Review
Copyright ©The Author(s) 2020.
World J Transplant. Jan 18, 2020; 10(1): 15-28
Published online Jan 18, 2020. doi: 10.5500/wjt.v10.i1.15
Table 4 Currently ongoing clinical trials concerning ex vivo machine perfusion in kidney transplantation
Name of studyRegistration numberDesignPInPrimary outcomeInterventionIncluded donorsResults
UnknownISRCTN91315246Non-randomizedCambridge90Graft function1 h NMPDiscarded kidneysNovember 2019
COPE-POMPISRCTN63852508RCTCOPE Essen262Graft survival 1yShort period HMP vs SCS onlyECD-DBDJuly 2019
COPE-COMPAREISRCTN32967929RCTCOPE Leuven162Kidney graft function 1 yHMP with oxygen vs HMP without oxygenDCD III↓ risk BPAR ↑ 1-y eGFR[44]
PIONCT03031067Case controlBologna20Graft function2 h HMP vs SCSECD -DBDFebruary 2018
PREDICTIONNCT02055950Case controlBergamo60Kidney functionHMP vs SCSECD-DBDAugustus 2018
UnknownNCT03837197RCTBologna260DGF2 h oxygenated HMP vs SCSECD-DBDDecember 2021
IMPULSIONNCT01170910RCTLyon162DGF6-8 h HMP vs SCSECDAugust 2016
Machine perfusion trialISRCTN83876362RCTCOPE Groningen654DGFNon-oxygenated HMP vs SCSDCD III and DBD↓ risk of DGF (OR 0.57) ↓ risk of graft failure (HR 0.52) ↑ allograft survival (94 vs 90%, P = 0.04)[27]
UnknownISRCTN15821205RCTCambridge400DGF1 h pre-transplant NMP vs SCSDCD III and IVJanuary 2021